KPIs & Operating Metrics(New)
Breakdown Of AssetsCollaboration Revenue BreakdownCollaboration Revenue Breakdown AnnualContractual ObligatonsCost Of SalesDeferred RevenueEmployee StatisticsGross Margin %Gross ProfitIncome (Loss) Before Provision For Income TaxNon Gaap ExpensesNon Gaap Expenses AnnualNon Gaap ProfitabilityNon Gaap Profitability %Non Gaap Profitability AnnualNon Gaap Profitability Annual %Opex As A % Of Total Revenue %OPEX SegregationProduct Revenue Breakdown AnnualProfitabilityProperty And Equipment, Net BreakdownRevenue By ProductRevenue By Product %Revenue By SegmentRevenue By Segment %Revenue By Segment AnnualRevenue By Segment Annual %Total Pmo Product Revenues, Net BreakdownTotal Pmo Product Revenues, Net Breakdown Annual
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherReceivables RefundsShares IssuedShares OutstandingShares OutstandingShares RepurchasedShort-Term Debt issuancesShort-Term Debt repayments
Ratios

Sarepta Therapeutics (SRPT) Gross Profit (2017 - 2026)

Sarepta Therapeutics' quarterly Gross Profit came in at $291.5 million in Q1 2026, up 6990.1% year-on-year from $4.1 million in Q1 2025, and up 559.16% quarter-over-quarter from $44.2 million in Q4 2025.

Sarepta Therapeutics has reported Gross Profit for 10 years, with the latest figure at $291.5 million in Q1 2026.

  • For the quarter ending Q1 2026, Gross Profit rose 6990.1% year-over-year to $291.5 million; the trailing twelve-month figure through Mar 2026 stood at $1.0 billion (down 14.22% YoY), and the FY2025 full-year result was $1.4 billion, down 14.17% from the prior year.
  • Gross Profit for Q1 2026 stood at $291.5 million, up from $44.2 million in the prior quarter.
  • The five-year high for Gross Profit was $526.1 million in Q4 2024, with the low at -$11.9 million in Q2 2023.
  • Average Gross Profit over 5 years is $236.0 million, with a median of $248.6 million recorded in 2025.
  • Year-over-year, Gross Profit slumped 107.58% in 2022 and soared 6990.1% in 2026.
  • Tracing SRPT's Gross Profit over 5 years: stood at $138.4 million in 2022, then surged by 203.04% to $419.4 million in 2023, then increased by 25.46% to $526.1 million in 2024, then slumped by 91.59% to $44.2 million in 2025, then surged by 559.16% to $291.5 million in 2026.
  • The last three Gross Profit figures came in at $291.5 million (Q1 2026), $44.2 million (Q4 2025), and $248.6 million (Q3 2025), per Business Quant data.